ArticlePloS one2026
RWDisEnh+: Enhancing disease-enhancer association prediction through multiplex-heterogeneous networks.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enhancers are critical regulatory DNA elements that, when dysregulated, can contribute to disease pathogenesis by altering gene expression. Although millions of enhancers have been identified through large-scale genomic projects, their associations with human diseases remain largely uncharacterized, emphasizing the need for robust computational approaches. In our previous work, we developed RWDisEnh, a network-based method that integrates a shared gene-based enhancer network with a disease similarity network within a heterogeneous framework to predict disease-enhancer associations. In this study, we present RWDisEnh+ , an enhanced version of RWDisEnh that incorporates a sequence-based enhancer similarity network into a multiplex-heterogeneous network to improve prediction performance. Using an extended random walk with restart (RWR) algorithm, RWDisEnh+ allows information to propagate across disease and enhancer layers, leveraging both gene-based and sequence-based similarity features to rank candidate enhancers for each disease. Comprehensive evaluation using 3-fold cross-validation demonstrated that RWDisEnh+ achieves an average AUC of 0.874, outperforming RWDisEnh's AUC of 0.819. Moreover, RWDisEnh+ identifies a larger number of evidence-supported disease-enhancer associations across top-k rankings, including 10 enhancers linked to seven diseases such as asthma, rheumatoid arthritis, and type 2 diabetes. GWAS validation and pathway enrichment analyses further reveal that these predicted associations are enriched in immune, inflammatory, and metabolic pathways, highlighting their biological relevance. Overall, RWDisEnh+ provides a stable and effective framework for predicting novel disease-enhancer associations, offering new insights into enhancer-mediated gene regulation and the genetic architecture of complex diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.